Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.40 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213579 | 0.87 | LMNA (0.43) | WEE1KDRMAP4K4AURKBSTK17A | |
| SCHEMBL214296 | 0.85 | CHEK2 (0.43) | HRH3BRAFMET | |
| SCHEMBL216121 | 0.84 | KDM4E (0.38) | LMNAMAPK1HIF1AMETPRKAA1 | |
| SCHEMBL214940 | 0.83 | HDAC6 (0.38) | KDRLCKCHEK1MAP4K4CSF1R | |
| SCHEMBL215459 | 0.80 | CHEK2 (0.46) | KDRFLT3SRCFGFR1ABL1 | |
| SCHEMBL214859 | 0.80 | CHEK2 (0.47) | KDRCHEK1FLT3ABL1PDGFRB | |
| SCHEMBL214530 | 0.77 | HRH3 (0.49) | HRH3KDRLCKCHEK1MAP4K4 | |
| SCHEMBL214015 | 0.74 | MAOB (0.53) | KDR | |
| SCHEMBL214720 | 0.74 | HCAR1 (0.35) | KDRABL1EPHB4MAPK1MAPT | |
| SCHEMBL215076 | 0.74 | CHEK2 (0.47) | FGFR1BRAFLMNAMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | HRH3 1553/4885WEE1 1480/4885KDR 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.